Notes

Choosing The Right Names Of Company In Denmark
Bekey


A List Of Danish Biotech Companies If you're seeking accurate data on Danish biotech firms, consider using a service like BoldData. This company's database includes information from Central Business Register and Danish Chambers of Commerce. The accuracy of the data will assist you in creating an effective marketing campaign for your biotech business. BoldData's data can help you to make your campaign more specific.

Orphazyme

A late-stage biopharmaceutical company Orphazyme is in the process of developing a new treatment for the neurodegenerative disease Niemann-Pick type C. The company has a lead candidate in development , Arimoclomol. The company plans to file an application for marketing authorization with the EMA in the second quarter of 2020.

The company has a long tradition of focussing on rare diseases. It was established by Thomas Kirkegaard and Marja Jaattela in the year 2010. They have been focusing their efforts on lysosomal storage disorders particularly.

Symphogen

French pharmaceutical company Servier has agreed to purchase Symphogen Symphogen, a Danish biotech company that has built an antibody discovery platform to aid in cancer treatments. This acquisition will enhance Servier's antibody pipeline. The two companies have been working together in the area of immuno-oncology for the past two years. The acquisition will allow Servier to fully leverage Symphogen's technological capabilities and expertise.

Symphogen has a solid management team which is diverse and knowledgeable. Symphogen's CEO Kirsten Drejer, is an industry veteran with a track record of establishing an extensive pipeline and helping to propel Symphogen to a solid financial position. The company also has assets with positive clinical data.

Galecto Biotech

Galecto Biotech is a Danish biotech company that creates innovative medicines to treat serious ailments. Galectin-3 is the most prominent product candidate. This protein is involved in a variety of immune and inflammatory processes. The company is currently running clinical trials to treat idiopathic lung fibrosis. It has joined forces with Bristol-Myers Squibb, and plans to start more clinical trials for fibrotic disorders.


Galecto Biotech's products were developed with a research technology that targets galectin-3. The company's product development teams are focused on the development and commercialization of chemically derived therapeutic drugs however, they're not limited to this. The company is also in advanced clinical trials using its galectin modulator. This could result in a cure for asthma and nasal polyposis.

Novo Nordisk

In the United States, Dicerna Pharmaceuticals has been purchased by the biotech company. Dicerna has previously developed medicines based upon RNA interference. This blockages certain genes that cause diseases.

The company plans to invest a total of 17 billion Danish kroner in three new manufacturing facilities. It will also expand an existing facility in Kalundborg, Denmark. The new facilities will provide more capacity throughout the global value chain. They will also increase the production of oral and injectable products. All new facilities will come with cutting-edge production technology.

Novozymes

Novozymes, a Danish biotechnology company, specializes in industrial enzymes. The company has a variety of markets for its products and its revenues are largely generated in industries like bio-energy, agriculture household care, and wastewater solutions. Novozymes was established in 1988, and is headquartered in Copenhagen in Denmark.

The Danish biotech company has a long track record of success in product roll-out. Its predecessor, Nordisk Insulinlaboratorium, launched its first enzyme, trypsin in 1941. The enzyme was initially used for softening leather. The company also invented the process of fermentation that allows enzyme production. It created the first enzyme for detergent production in the late 1980s: lipolase. This enzyme enhanced the freshness and quality of white breads and buns.

Lilly

Many of the world's most well-known biotech companies are located in Denmark. Biotechnology is used by these companies to fight cancer, create vaccines, and provide other medical solutions. Oncology Venture ApS specializes in research and development in the area of cancer. Other notable companies include AquaGreen, an Danish biotech engineering firm, and STipe Therapeutics, which harnesses the immune system's natural defense mechanisms to fight cancer. Acesion Pharma, a Danish biotech firm, is creating drugs to treat atrial fibrillation.

Denmark and Sweden have a long history in the biotechnology and medical technology industries. They are among the top five pharmaceutical exporters around the world. Denmark also boasts one of the highest per capita R&D expenditures in the European pharmaceutical industry, second only to Switzerland. Additionally, 60 percent of the pharmaceutical activities in Scandinavia are concentrated in the Medicon Valley, a Danish-Swedish cross-border cluster.

Innovent

Innovent Biotech recently purchased exclusive rights for Eli Lilly's cancer medicines in China. Innovent will be able to regulate the pricing, marketing, and distribution of these drugs. The companies plan to collaborate in the development of therapies for medical issues that are major and unmet including cancer and eczema.

Innovent has a large pipeline, including 16 potential products. Seven of these are currently in clinical trials. Seven is also working with Eli Lilly on co-development of three cancer treatments in China. Another Danish biotech company, Ascentage, has partnered with Oriza Ventures and the Chinese state-owned SDIC Fund Management.



Here's my website: https://www.cooley.digital/references/